Development of drug resistance is the inevitable consequence of incomplete suppression of virus plasma levels in HIV-1-infected patients treated with highly active antiretroviral therapy. Resistance mutations previously characterized have been found in B subtype viruses of developed countries. Moreover, mutation profiles for non-B and more divergent B subtype viruses found in developing countries shall be analyzed together with their ex vivo phenotyping in order to establish an exact correlation between the genotyping data and the clinical management counseling for those uncommon virus subtypes. In the present study, we evaluated the mutation profile for individuals infected with B subtype and non-B subtype viruses. Viral DNA fragments corresponding to the RT gene were amplified, sequenced, and subtyped. Phenotyping analysis for reverse transcriptase nucleoside (NRTI) and nonnucleoside inhibitor susceptibility was performed using the recombinant virus assay technology. Brazilian non-B subtypes (subtype F, n ϭ 4, and subtype A, n ϭ 1) isolates showed essentially the same B subtype mutation profile, presenting an NRTI drug resistance with similar MIC50% and MIC90% values for all drugs analyzed regardless of their subtypes. A strong cross-resistance phenotype among AZT, 3TC, and abacavir could be seen in all isolates analyzed. A novel result was that some RT sequences not only revealed the presence of G333D/E mutations but also correlated to the presence of mutation T386I that could abrogate the M184V-surpassing effect of L210W or L210W plus G333D/E. These findings suggest that Brazilian non-B subtype HIV-1 strains use an identical RT drug resistance mutation pattern when compared to B isolates and will contribute to the validation of the genotypic and phenotypic tests in these predominant worldwide-spread viral variants.
INTRODUCTION
Recent development of a new generation of drugs against HIV led to drastic changes in antiretroviral therapy and treatment of AIDS. Antiretroviral drug combinations including two nucleoside reverse transcriptase inhibitors (NRTI) and/or nonnucleoside reverse transcriptase inhibitors (NNRTI) and one or more protease inhibitors can reduce the viral load in plasma to undetectable levels and provide durable clinical benefits (Collier et al., 1996; Vella et al., 1996) . However, complete suppression of HIV-1 replication is rarely achieved with mono-and bitherapies, which have a transient effect due to virus drug resistance (Carpenter et al., 1996) . For that reason, current guidelines to obtain benefits from antiviral therapy recommend at least a triple-drug combination, the so-called highly active antiretroviral therapy (HAART). Not all patients respond to HAART and the development of drug resistance remains one of the most serious obstacles to sustained suppression of HIV (Shafer et al., 1998; Ledergerber et al., 1999) . Continuous in vivo HIV replication and the error-prone nature of the viral reverse transcriptase are the driving forces for generation of drug resistance (Coffin, 1996) . Moreover, recent studies identified a replication-competent HIV-1 reservoir in patients under HAART, raising serious concern regarding whether antiviral therapy can eradicate HIV-1 (Finzi et al., 1997; Zhang et al., 1999; Furtado et al., 1999) .
HIV replicates as complex and dynamic distributions of mutant genomes termed viral quasispecies (Domingo et al., 1997) , which constitute an enormous reservoir of genetic variants. This quasispecies structure represents an important obstacle in the control of the infection through drug therapy (Domingo et al., 1997) . The repeated selection of HIV-1 variants resistant to antiretroviral agents is an important concern in the treatment of patients under HAART with any of the major nucleoside and nonnucleoside reverse transcriptase inhibitors (for details see Fig. 4 and the web site http://www.viralresistance.com). However, almost all studies on HIV-1 drug susceptibility have been performed in developed countries, where subtype B still dominates the epidemic. Similarly, the resistance mutations selected during antiretroviral treatment were only studied with subtype-Binfected patients. These facts make the study of non-B subtype isolates resistant to antiretroviral agents an important issue for the characterization of non-B mutations related to drug resistance.
As the largest country in South America, Brazil has also been the one most heavily affected by the HIV/AIDS epidemic. The Brazilian epidemic is characterized by multiple HIV-1 group M subtypes, primarily subtype B and the less prevalent subtype F, but also subtypes C and D (Morgado et al., 1994; Sabino et al., 1996; Tanuri et al., 1999) . Subtype F is the most prevalent non-B variant and represents approximately 18% of HIV-1 isolates from southeastern Brazilian cities. An increasing prevalence of subtype C infections has also been recognized in Brazilian southernmost states (WHO Network for HIV Isolation and Characterization, 1994) . In addition, the presence of recombinants, potential mosaics, and dual infections has been documented (Janini et al., 1996; Corlnelissen et al., 1997) . Those group M subtypes found in Brazil are also originally endemic to various developing countries throughout the world (McCutchan et al., 1996; Janssens et al., 1997) , and they need to be evaluated for their susceptibility to RT inhibitors and mutation profiles related to drug resistance. This study documents the genotypic and phenotypic analyses of reverse transcriptase gene from 14 HIV-1 B and non-B subtype isolates infecting Brazilian patients who failed HAART.
RESULTS
All patients studied were in stage 4 based on the WHO staging system and they were all antiretroviral experienced, with exposure to two to five different nucleoside analogues for a mean treatment duration of 32 months (31.93 Ϯ 3.79 mean SD). NNRTI were absent from the drug regimens of study patients, and ritonavir, saquinavir, and indinavir were the protease inhibitors utilized to compose the HAART cocktail (Table 1 ). Most patients were under different NRTI mono-and bitherapies previous to HAART adherence (Table 1 and Fig. 1) .
To determine the RT gene subtype classification of these 14 HAART nonresponder isolates, phylogenetic trees were performed based on "palm and finger" RT region sequences (Fig. 2) . Five of 14 (35.6%) non-B subtype individuals were found in this group of samples. Four specimens were subtype F, and other 9 samples (64.4%) belong to subtype B. Sample ERRJ16 couldn't be assigned to any specific subtype group based on the RT region analyzed, presenting a bootstrap value of 36% with the nearest F subtype branch. Of note, most of the samples presented branch lengths much larger than the A, B, and F standard sequences used to construct the phylogenetic tree. In order to clarify the subtype assignment of sample ERRJ16, the gag-p24 region of this isolate and all non-B infected individuals were analyzed. Figure  3 shows the phylogenetic tree representing the analysis of these samples where longer branch lengths continued to be observed when compared to the standards se- quences. These results indicated that sample ERRJ16 is of A subtype, while samples ERRJ15, ERRJ17, ERRJ18, and ERRJ19 were grouped with subtype F clade.
Although all patients described here experienced HAART failure, who were all experienced in previous NRTI therapies, this cohort sampling population showed a different treatment profile when individuals infected with B subtype and non-B subtype viruses were compared (Fig. 1) . The Brazilian non-B viruses induced a therapy failure in patients with comparable times of treatment (27.8 Ϯ 4.6 months average Ϯ mean SD, versus 34.2 Ϯ 5.3 months of B-virus-infected patients; one-tailed unpaired t test, P ϭ 0.1918) to the B counterpart as well the number of NRTI drugs used during this time of treatment (3.6 Ϯ 0.2 drug mean Ϯ mean SD versus 4.1 Ϯ 0.3 drug mean of B-virus-infected patients; one-tailed unpaired t test, P ϭ 0.1279).
In order to study the genotypes for NRTI and NNRTI resistance, all 14 amino acid sequences of reverse transcriptase palm and finger regions were deduced and aligned. The alignment of 14 B and non-B Brazilian samples is depicted in Fig. 4 . Overall, the mutation patterns found were compatible with the drug regimen implemented in each patient. The main mutation pattern found in Brazilian isolates regardless of the subtype involved was the association of K70R, M184V, and T215F/Y. Mu- tation L210W was found in samples ERRJ16, ERRJ18, ERRJ23, ERRJ25, ERRJ26, ERRJ27, and ERRJ28. The multidrug resistance mutation Q151M was found in sample ERRJ20 and in this case was associated with Y115F and F116Y. Mutations related to NNRTI resistance were absent in all 14 samples studied.
Phenotyping analysis was performed using the recombinant virus assay technology (VIRCO). Recombinant virus was generated carrying the 2.2-kb pol fragment amplified from each of the 14 samples and exposed to NRTI (AZT, 3TC, ddI, ddC, and d4T) and NNRTI (nevirapine, delavirdine, efavirenz) in MT4 cell cultured. The RT phenotyping results are shown in Table 2 . Most of the samples (9 of 14) were simultaneously resistant to AZT and 3TC. This was mainly related to the presence of L210W and/or G333D/E associated with K70R, M184V, and T215F/Y mutations. One exception for this was found in sample ERRJ20 where the multidrug resistance mutation pattern (Q151M, Y115F, and F116Y) was identified. In fact, L210W mutation alone, or in association with G333D/E, was responsible for abolishing the AZT-resistance suppressive background due to the M184V mutation. The mutational feature of the uppermost C-terminal region of RT was established by analysis of the mutation profile reports of the 2.2-kb pol amplicons generated previous to the phenotyping assay. This analysis not only revealed the presence of G333D/E mutations in some RT sequences but also correlated with the presence of a novel mutation T386I that could abrogate the M184V-surpassing effect of L210W or L210W plus G333D/E (Table 3) . At different levels, the M184V background interference over the AZT-resistance mutation profile is biased by the presence of L210W or L210W ϩ G333D/E and favored by the T386I mutation. The aspartic acid residue at position 333 associated to L210W seems to be more effective in doing so than its glutamic acid counterpart, as revealed by different IC50% AZT fold resistance between samples ERRJ25 and -27.
Most of these AZT and 3TC resistant strains were cross-resistant to abacavir, an antiretroviral compound not used in these patients. Although most of patients were using ddI in their drug regimen, only three samples (ERRJ16, ERRJ20, and ERRJ27) showed a low-level resistance to this NRTI. ddI resistance in sample ERRJ27 was apparently associated to the L74I mutation. On the other hand, the ddI resistance in samples ERRJ20 was related to Q151M multidrug resistance mutation. No main mutations related to ddI resistance were found in sample FIG. 3 . Phylogenetic analysis of HIV p24 gag isolates. Sequence isolates were compared to 16 reference HIV-1 group M subtypes and 2 reference HIV-1 group O, available in the Los Alamos database. Sequence cpz was used as the outgroup. Aligned fragments were analyzed as described under Materials and Methods, and bootstrap values for 2000 replicates are listed at the major subtype branches. Brazilian isolates sequenced in this study are italicized. The scale bar shows the ratio of nucleotide substitution for a given horizontal branch length. Vertical distances are for clarity only.
FIG. 2. Phylogenetic analysis of HIV RT isolates compared to 18
reference HIV-1 group M subtypes and 2 reference HIV-1 group O, available in the Los Alamos database. Sequence cpz was used as the outgroup. Aligned fragments were analyzed as described under Materials and Methods, and bootstrap values for 2000 replicates are listed at the major subtype branches. Brazilian isolates sequenced in this study are italicized. The scale bar shows the ratio of nucleotide substitution for a given horizontal branch length. Vertical distances are for clarity only.
ERRJ16. In the same way, although D4T was heavily used, only sample ERRJ20 showed some level of resistance to this analog probably related to the Q151M multidrug resistance mutation. Of note, no level of resistance to nevirapine, delavirdine, or efavirenz could be observed in all samples studied. Although the mutation V106I could be found in sample ERRJ25, no level of resistance to nevirapine was observed by the phenotyping assay. By taking all these results together we could not observe any significant difference in the level of   FIG. 4 . Amino acid alignment of RT "palm and finger" sequences. Mutations commonly related to NRTI and NNRTI resistance are depicted at the top (AZT, zidovudine; 3TC, lamividine; ddI, didanosine; ddC, zalcitabine; D4T, stavudine; ABC, abacavir; NVP, nevirapine; DLV, delavirdine; EFV, efavirenz; MNR, multinucleoside resistance (see web site: http://www.viral-resistance.com), and alignment of deduced protein sequence from HIV-1 RT isolates is shown at the bottom. Nucleotide sequences were translated, aligned, and compared with the SF2 isolate sequence as a consensus of B subtype, deduced from the Los Alamos database. Boldface letters indicate the substitutions that confer primary drug resistance to NRTI and NNRTI, italicized letters refer to secondary substitutions, and the underlined letters indicate the amino acid differences between subtypes. Dots denote sequence identity with the consensus sequence. phenotypic resistance to NRTI when B and non-B subtype isolates were compared.
DISCUSSION
Plasma viral load (VL) is commonly used as an independent predictor of clinical progression (Mellors et al., 1995) and is a useful tool for monitoring response to therapy (Ledergerber et al., 1999) . The initial choice of the 14 HAART nonresponder patients was based on the VL response, which was at least 2 logs higher than that of HAART responders in the AIDS clinics of the two hospitals enrolled in this study (data not shown). By using this virological criterion, we could find mutations related to NRTI resistance in all patients analyzed and these substitutions accorded with the drug regimen implemented. Overall, the reverse transcriptase genotyping corroborated the phenotypic resistance assay results for each isolate, regardless of the virus subtype. We could observe a correlation between L210W and AZT/3TC dual resistance, except when coexisting with T386I. Previous studies have shown that just one primary substitution was sufficient for in vivo development of zidovudine resistance at significant levels, but multiple substitutions that include G333D/E and/or L210W are required for the same level of zidovudine resistance in strains harboring the M184V mutation related to 3TC resistance. This need for multiple substitutions may be one of the mechanisms that explains the sustained antiretroviral response of the 3TC-zidovudine combination (Nijhuis et al., 1997) . In Brazilian samples, mutational analysis indicates that L210W is far more prevalent and it was found in 67% of the isolates (four of six) that showed this mutation together with the M184V mutation. The substitution G333D/E is likely to have a minor role in the resistance phenotype, generally related to L210W. When it was found apart from L210W, even in the absence of T386I, G333D could not correlate with the dual AZT/3TC resistance phenotype (sample ERRJ20). Although this is a potentially interest- e Subtype based on gag-p24 phylogeny.
TABLE 3
Susceptibility to AZT in Samples Carrying L210W, G333D, and/or T386I in the M184V Background
a Fold increase in the mean IC50% relative to the mean IC50% of the wild type.
b Boldface indicate resistance level Նfourfold as determined to be significant. c ϩ and Ϫ represent the presence and absence of mutation, respectively.
ing finding, it needs to be confirmed by cloning this substitution alone and with the other mutations in a different RT background before its significance can be assessed. The mutation Q151M found in sample ERRJ20, together with a secondary mutation pattern (A62V, V75I, F77L, and F116Y) correlated with a multinucleoside resistance phenotype, was responsible for another case of AZT/3TC resistance in the presence of M184V.
There was a strong association between the resistance to AZT and 3TC and the loss of sensitivity to abacavir, an antiretroviral compound never used in the patients' regimen. This observation was previously reported in a European study where cross-resistance was not commonly observed in that lamivudine-treated cohort and M184V mutation per se was not expected to compromise subsequent treatment with NRTIs such as didanosine-stavudine or combinations containing abacavir . Although all samples showed resistance to NRTIs at genotypic and phenotypic levels, there were no mutations related to NNRTI resistance as well as phenotypic resistance to this class of antiretroviral drugs. This work shows that these two distinct subtypes (B and F) use basically the same mutation profile to reach resistant phenotypes.
The observation of large branch lengths in the phylogenetic trees for Brazilian resistant sequences is probably an effect of the accumulation of primary and secondary mutations related to reverse transcriptase inhibitor resistance due to drug-selective pressure.
Studies with isolates from untreated subjects showed that mutations related to protease inhibitors, NRTI, and NNRTI resistance could be found in B and non-B subtype viruses as natural polymorphisms suggesting that the HIV-1 pol region has sufficient in vivo fitness flexibility for varying in critical sites (Lech et al., 1996; Cornelissen et al., 1996) . It is important to mention that although subtype B and F RT sequences differ from about 30 nucleotides and only two amino acids in the palm-finger region, these mutations and substitutions are not related to NRTI or NNRTI resistance (Brindeiro et al., 1999) . In the same way, in vitro studies performed with subtypes A, B, C, and E as well as group O (Descamps et al., 1997b) demonstrated similar drug susceptibility among these variants and subtype B. On the other hand, subtype D isolates showed a higher MIC50% and MIC90% when compared with the other subtypes studied and this was correlated with the faster in vitro growth pattern . In the same way, subtype G strain showed a decreased susceptibility to protease inhibitors and presented an M36I substitution as a natural polymorphism (Descamps et al., 1997a) . Additionally, B and non-B isolates have comparable levels of resistance in the in vitro tests performed, suggesting that these mutations induce similar modifications in the enzyme three-dimensional structure.
Non-B subtype infections are becoming more common in Europe and North America (Brodine et al., 1995; Fransen et al., 1996; Lasky et al., 1997) and these variants dominate the epidemic in the rest of the world (McCutchan et al., 1996) . Moreover, some countries in the developing world are sponsoring large HIV treatment programs with drug combinations including NRTI and NNRTI. The data presented in this work clearly show similar mutation patterns related to NRTI resistance and the phenotypic level of drug resistance in vitro between Brazilian B and non-B isolates. These observations may contribute to the validation of the genotypic and phenotypic tests in these predominant worldwide-spread viral variants.
MATERIALS AND METHODS
Samples. From April through December 1998, blood samples were collected at Hospital Universitá rio Gaffré e & Guinle and Hospital dos Servidores do Estado in Rio de Janeiro. Fourteen samples were selected prospectively and the inclusion criteria for the study were that patients have AIDS (CD4 counts Ͻ200/mm 3 ) and have had at least 6 months in HAART. The basic criteria to segregate these samples were the viral loads after HAART implementation. A viral load drop lower than 1 log after implementation of HAART was considered a failure in the antiretroviral therapy. These selected patients were also evaluated for compliance to the treatment and only individuals referring good compliance to antiretroviral therapy were included in this study. All patients were asked to read and sign a consent form before sample collection. Epidemiological and clinical parameters are summarized in Table 1 and Fig. I . Viral load measurements were done with NASBA methodology (Organon Teknika, The Netherlands). This method has a lower limit of detection, around 400 copies of HIV RNA/ml, and is able to measure with equal efficiency B and non-B isolates in plasma (de Baar et al., 1999) .
Nucleic acid extraction, cDNA synthesis, and polymerase chain reaction (PCR). Genomic DNAs from PBMCs and plasma viral RNA were isolated using a QIAamp blood kit (Qiagen Inc., Chatsworth, CA) according to the manufacturer's protocol and stored at Ϫ70°C. The synthesis of cDNA occurred in the presence of avian myeloblastosis virus RT (Stratagene) at 42°C. Two different HIV-1 genomic regions were targeted for PCR amplification: gag p24 (from provirus) and pol Rt (from provirus and cDNA), using primers described in Table 4 . Nested PCR amplification was performed as previously described (Tanuri et al., 1999; Janini et al., 1996) using for both HIV regions a mixture containing 5 l of cDNA or genomic DNA (or 2 l of the outer PCR product), 5 l of 10ϫ Taq buffer, 5 l of 25 mM MgCl 2 solution, 1 l of 10 mM (each) deoxynucleoside triphosphates, 1 l (25 pmol) of each PCR primer, 31.5 l of H 2 O (or 34.5 l for the nested reaction), and 0.5 l (2.5 U) of AmpliTaq polymerase (Perkin-Elmer). For both outer and nested PCR rounds, 35 cycles were performed, with an annealing temperature of 57°C, extension at 72°C, and denaturation at 94°C over 30 s each. PCR products were purified using QIAamp PCR purification kit (Qiagen Inc.) according to the manufacturer's instructions.
DNA sequencing. Both strands of the PCR fragments were directly sequenced using internal (nested) PCR primers and the ABI Prism dye terminator cycle sequencing reaction kit (Perkin-Elmer, Foster City, CA). The sequence reaction was fractionated and analyzed using an automated sequencer (ABI Model 310, Perkin-Elmer) according to the manufacturer's protocol. Sequences described in this studied have been assigned the followed GenBank Accession Number: gag p24 (AF165562-66) and pol RT (AF180667-80).
Phylogenetic analyses. cDNA RT and provirus p24 sequences were analyzed with the sequence editor DNASIS version 2.1 software (Hitachi, NJ) and manually edited. Alignments were performed using CLUSTAL W (Thompson et al., 1994) . For phylogenetic analyses, the neighbor-joining method was used (Saitou and Nei, 1987) . Evolutionary distances were estimated using the Kimura two-parameter method. Construction of trees and their bootstrap test were conducted using the computer program MEGA (Kumar et al., 1993) with 2000 replications, with representative standards belonging to different subtypes obtained from the database of Los Alamos National Laboratory. The SIVcpz sequence was used as an outgroup.
Phenotyping. The detection of HIV-1 phenotypic RT inhibitor resistance was performed using a recombinant virus assay technology (VIRCO). Briefly, HIV-1 RNA was extracted from plasma samples, and a 2.2-kb fragment containing the entire HIV-1 pol (protease and reverse transcriptase) coding sequence was amplified by nested reverse transcription PCR. Sequences were generated using an ABI Prism automated sequencing machine and analyzed in a HIV-genotyping software from VIRCO, confirming the previous genotyping data. A mutation profile report was generated for each sample when compared with the prototypic MN isolate RT sequence. The pool of pol coding sequences of each sample was then cotransfected into CD4ϩ T lymphocytes (MT4) with the pGEMT3 (PRT plasmid carrying the defective pol HIV genomic cDNA). Homologous recombination led to generation of a chimeric virus containing pol sequences derived from the patients' virus. The susceptibility of the chimeric virus to all currently available RT inhibitors was determined by an MT4 cell-3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide-based cell viability assay in an automated system as previously described . 
